VRNA - Verona Pharma plc

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
6.35
+0.25 (+4.10%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close6.10
Open6.25
Bid6.25 x 1100
Ask7.94 x 1100
Day's Range6.17 - 6.39
52 Week Range5.52 - 18.20
Volume9,965
Avg. Volume8,267
Market Cap81.57M
Beta (3Y Monthly)-1.10
PE Ratio (TTM)N/A
EPS (TTM)-2.34
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est31.80
Trade prices are not sourced from all markets
  • GlobeNewswire12 days ago

    Verona Pharma Granted Key EU Patent Related to Late-stage COPD Clinical Candidate Ensifentrine

    Verona Pharma plc (VRP.L) (VRNA) (“Verona Pharma”), a clinical stage biopharmaceutical company focused on respiratory diseases, is pleased to announce that the European Patent Office has recently granted an additional key patent relating to its lead development candidate, ensifentrine. The patent provides intellectual property protection throughout Europe out to 2035 for a suspension formulation of ensifentrine (RPL554) suitable for nebulized administration. A corresponding patent has already issued in the US.

  • GlobeNewswire17 days ago

    Grant of Options and RSUs and PDMR Dealings

    LONDON, April 04, 2019 -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing.

  • GlobeNewswire26 days ago

    Verona Pharma to Present at H.C. Wainwright Global Life Sciences Conference

    Verona Pharma plc (VRP.L) (VRNA) (“Verona Pharma”), a clinical stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, today announces that the Company’s management team will present and conduct face-to-face meetings at the H.C. Wainwright Global Life Sciences Conference. Jan-Anders Karlsson, PhD, CEO of Verona Pharma, is scheduled to present on Monday, April 8th at 11:30 am BST. Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs.

  • GlobeNewswire27 days ago

    PDMR Dealing

    LONDON, March 25, 2019 -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing.

  • GlobeNewswirelast month

    2018 Annual Report and Accounts and Notice of AGM 

    LONDON, March 22, 2019 -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a clinical stage biopharmaceutical company focused on developing and commercializing.

  • GlobeNewswirelast month

    Dr. Martin Edwards Joins Verona Pharma as Non-Executive Director

    LONDON, March 21, 2019 -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical stage biopharmaceutical company focused on developing and commercializing.

  • GlobeNewswire2 months ago

    Verona Pharma Reports Positive Interim Data with Ensifentrine Dry Powder Inhaler Formulation in First of Two-Part Phase 2 Clinical Trial in COPD

    Verona Pharma plc (VRP.L) (VRNA) (“Verona Pharma”), a clinical stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces positive interim efficacy and safety data from part one of a two-part Phase 2 clinical trial of a dry powder inhaler (“DPI”) formulation of ensifentrine in patients with moderate-to-severe chronic obstructive pulmonary disease (“COPD”). The positive data support initiation of the second part of the Phase 2 trial to evaluate the ensifentrine DPI formulation in patients with moderate-to-severe COPD over one week of twice-daily treatment.

  • GlobeNewswire2 months ago

    Verona Pharma to Present at Cowen and Company 39th Annual Health Care Conference

    Verona Pharma plc (VRP.L) (VRNA) (“Verona Pharma”), a clinical stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, today announces that the Company’s management team will present and conduct face-to-face meetings at the Cowen and Company 39th Annual Health Care Conference. Jan-Anders Karlsson, PhD, CEO of Verona Pharma, is scheduled to present on Wednesday, March 13th at 10:00 am ET.  A webcast of the presentation will be available on the "events and presentation" page of the "investors" section of Verona Pharma’s website.

  • GlobeNewswire2 months ago

    Verona Pharma Reports Financial Results for Full Year Ended December 31, 2018 and Provides Clinical Development Update

    LONDON, Feb. 26, 2019 -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (Verona Pharma), a clinical-stage biopharmaceutical company focused on developing and commercializing.

  • GlobeNewswire2 months ago

    Verona Pharma to Announce Financial Results for Full Year ended December 31, 2018 and Provide Clinical Development Update

    Verona Pharma plc (VRP.L) (VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces that it will report its audited financial results for the full year ended December 31, 2018 on Tuesday, February 26, 2019. Verona Pharma will host an investment community conference call at 8:00 a.m. Eastern Standard Time (2:00 p.m. Greenwich Mean Time) on Tuesday, February 26, 2019 to discuss the full year financial results and provide a clinical development update.

  • GlobeNewswire2 months ago

    Verona Pharma to Present at Upcoming Investor Conferences

    LONDON, Feb. 04, 2019 -- Verona Pharma plc (AIM: VRP) (NASDAQ: VRNA) (“Verona Pharma”), a clinical stage biopharmaceutical company focused on developing and commercializing.

  • Verona Pharma Works Sees Hammer Chart Pattern: Time to Buy?
    Zacks3 months ago

    Verona Pharma Works Sees Hammer Chart Pattern: Time to Buy?

    Verona Pharma plc (VRNA) has been struggling lately, but the selling pressure may be coming to an end soon.

  • Verona Pharma Enters Oversold Territory
    Zacks3 months ago

    Verona Pharma Enters Oversold Territory

    Verona Pharma PLC American Depositary Share (VRNA) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

  • GlobeNewswire3 months ago

    Verona Pharma Reports Encouraging Top-Line Data from Three-Day Phase 2 Trial Evaluating Nebulized Ensifentrine (RPL554) on Top of Dual Bronchodilator Therapy for COPD Maintenance Treatment

    LAMA/LABA therapies are commonly used in the maintenance treatment of patients with moderate to severe chronic obstructive pulmonary disease (“COPD”). Patients already receiving inhaled corticosteroid (“ICS”) therapy were allowed to continue to receive a stable dose of ICS throughout the study, thus providing additional data on “triple therapy” use.

  • Verona Pharma Sees Hammer Chart Pattern: Time to Buy?
    Zacks3 months ago

    Verona Pharma Sees Hammer Chart Pattern: Time to Buy?

    Verona Pharma has been struggling lately, but the selling pressure may be coming to an end soon.

  • GlobeNewswire3 months ago

    Verona Pharma Receives WHO Approval for “ensifentrine” as Recommended INN for RPL554

    Verona Pharma plc (VRP.L) (VRNA) (“Verona Pharma”), a clinical stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces today that the World Health Organization (“WHO”) approved “ensifentrine” as the recommended International Non-proprietary Name (“INN”) for the company’s drug candidate, RPL554. Ensifentrine is a first-in-class, inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 designed to have bronchodilator as well as anti-inflammatory properties, and is currently in development for the maintenance treatment of chronic obstructive pulmonary disease (“COPD”), cystic fibrosis (“CF”) and potentially asthma.

  • GlobeNewswire4 months ago

    Verona Pharma Appoints Kathleen Rickard, MD, as Chief Medical Officer to Lead Late Stage Clinical Development of RPL554

    Verona Pharma plc (VRP.L) (VRNA) (“Verona Pharma”), a clinical stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces the expansion of its global clinical development team with the appointment of Kathleen Rickard, MD, as Chief Medical Officer, and Tara Rheault, PhD, MPH, as Vice President of Research and Development Operations and Global Project Management. Drs. Rickard and Rheault will be based in the Company’s U.S. offices from where they will leverage their expertise to help drive global R&D activities.

  • GlobeNewswire4 months ago

    Verona Pharma Initiates Phase 2 Clinical Trial to Evaluate Dry Powder Inhaler Formulation of RPL554 for Maintenance Treatment of COPD

    Verona Pharma plc (VRP.L) (VRNA) (“Verona Pharma”), a clinical stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces today the initiation of a Phase 2 clinical trial to evaluate the pharmacokinetic (“PK”) profile, efficacy and safety of a dry powder inhaler (“DPI”) formulation of RPL554 in patients with moderate to severe chronic obstructive pulmonary disease (“COPD”).

  • GlobeNewswire5 months ago

    Verona Pharma plc Operational Update and Financial Results for the Three and Nine Months Ended September 30, 2018

    Initiated a Phase 2 trial of RPL554 as add-on to dual bronchodilator therapy for COPD maintenance treatment; enrolled last patient and dosing underway Progressed DPI and pMDI.

  • GlobeNewswire6 months ago

    Verona Pharma Completes Enrollment in Phase 2 Clinical Trial Evaluating Nebulized RPL554 as Add-on to Dual Bronchodilator Therapy for COPD Maintenance Treatment

    Verona Pharma plc (VRP.L) (VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces that is has enrolled the last patient in its Phase 2 clinical trial evaluating the effect of nebulized RPL554 as an add-on to dual therapy using long-acting anti-muscarinic / long-acting beta2-agonists (“LAMA/LABA”) and triple therapy (LAMA/LABA with an inhaled corticosteroid) in the maintenance treatment of patients with moderate to severe chronic obstructive pulmonary disease (“COPD”). A total of 79 patients with COPD have enrolled at sites in the U.S. and in the UK in this three way crossover study.

  • GlobeNewswire6 months ago

    Verona Pharma to Announce Interim Results for Nine Months Ended September 30, 2018 and Provide Clinical Development Update

    LONDON, Oct. 30, 2018 -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing.